Chimerix, a Durham-based drug developer that went public in April for more than $100 million, says in an SEC filing that “certain stockholders” are looking to sell their shares.
The shareholders were not identified. Neither was the number of shares to be sold.
“We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings,” Chimerix said in the filing.
Chimerix (Nasdaq: CMRX) shares closed at $21.91 on Monday. Its initial public offering priced at $14 per share.
The company “will not receive any proceeds from the sale of the shares,” Chimerix said.
The company’s focus is antiviral drugs that can be delivered orally,
Morgan Stanley and Cowen and Company are handling the offering.
Venture capital investors over the years have included Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management.
